1st Quarter - Report

ASTRAZENECA PHARMACEUTICALS LP for ASTRAZENECA PHARMACEUTICALS LP

Firm
Client
Income
—
Expenses
$1,060,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

FDA Patent Settlement legislation - House

LobbyistCovered position, as disclosed
SUSIE AHN —
MORGAN BRADLEY-JONES —
HELEN DWIGHT —
THERESA JOLIVETTE —
NATALIE MORRIS —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Health & Human Services, Dept of (HHS)

Pharmacy PHA

Medicare coverage Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D & B Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint

LobbyistCovered position, as disclosed
SUSIE AHN —
MORGAN BRADLEY-JONES —
HELEN DWIGHT —
JULIE GARNER —
THERESA JOLIVETTE —
NATALIE MORRIS —

Contacted: SENATE; Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES

Health Issues HCR

Value of Prescription Drugs Value Based Agreements (VBAs)- PAVE Act Biosimilars Rebate Reform Pricing Transparency: SPIKE Act, HR 2069 and STAR Act, HR 2113 Oncology Care Model - CMS Personalized Medicine H.R. 6, SUPPORT for Patients and Communities Act -House & Senate

LobbyistCovered position, as disclosed
SUSIE AHN —
MORGAN BRADLEY-JONES —
HELEN DWIGHT —
JULIE GARNER —
THERESA JOLIVETTE —
NATALIE MORRIS —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE; Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 2069 (116th), H.R. 6 (116th), H.R. 2113 (116th)

Medicare/Medicaid MMM

Medicare Part D Coverage and Reimbursement Medicare Part D Non-Interference Legislative proposals to change Medicare Part D Medicare Part B coverage and reimbursement Medicaid Coverage Rebate reform Medicare Part B IPU proposed rule - House Changes to the Medicaid Drug Rebate Program (AMP Cap) - House Medicare Part B Intl. Pricing Index ANPRM - Senate & House & CMS

LobbyistCovered position, as disclosed
SUSIE AHN —
MORGAN BRADLEY-JONES .
HELEN DWIGHT —
JULIE GARNER —
THERESA JOLIVETTE —
NATALIE MORRIS —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE; Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.